Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
seasonal influenza quadrivalent vaccine
- Development stage
- Approved
- Lead developer
- AstraZeneca
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
The seasonal influenza quadrivalent vaccine (specifically referring to VN-0104/FluMist Quadrivalent) is a live attenuated influenza vaccine (LAIV) developed by AstraZeneca and licensed to Daiichi Sankyo for the Japanese market. Administered as an intranasal spray, it contains four cold-adapted, temperature-sensitive influenza virus strains (two Type A and two Type B). Unlike inactivated vaccines, LAIV replicates locally in the nasopharynx, stimulating mucosal IgA production and T-cell mediated immunity in addition to systemic IgG responses, thereby mimicking natural infection. The vaccine was approved in Japan in March 2023 for use in children and adolescents aged 2 to 18 years. Clinical development is also ongoing for healthy adult populations in Japan.
- Brand names
- FluMist QuadrivalentFluMist
- Other names
- live attenuated influenza vaccine quadrivalentLAIV4LAIV-4LAIV 4influenza vaccine live attenuated quadrivalent
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on seasonal influenza quadrivalent vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on seasonal influenza quadrivalent vaccine.